LUND, Sweden, Feb. 20, 2023 /PRNewswire/ -- Immunovia will
publish its full year 2022 results on February 23, 2023 at 8:30
am CET. Analysts, investors and media are invited to a
webcast teleconference on the same day at 11:00 CET. The report together with the
presentation slides will be available at www.immunovia.com
Philipp Mathieu, CEO and
President, Jeff Borcherding, CEO
Immunovia, Inc. and Karin Almqvist Liwendahl, CFO, will present on
Immunovia's development. The presentation will be held in English
and be followed by a Q&A session. You are welcome to join via
webcast or phone, see details below.
Telephone numbers and webcast
Call any of the numbers below to participate via telephone.
Please dial in a few minutes before the presentation starts.
Sweden: +46 (0)8 5051
0031
United Kingdom: +44 (0) 207 107 06
13
United States: +1 (1) 631 570 56
13
Link to the
webcast: https://link.edgepilot.com/s/94d445d8/kGg7TnRc0kW8IMCMe-92zw?u=http://creo-live.creomediamanager.com/d1d6a3da-b961-48c9-beb8-3d4026f05d6f
To ask questions, it is necessary to dial in. A recording of the
presentation will be available on Immunovia's website.
For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
46 70 911 56 08
The information was submitted for publication on February 20, 2023, at 15:20 am CET.
About Immunovia
Immunovia is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information see:
www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
CONTACT:
The following files are available for download:
|
https://mb.cision.com/Main/13121/3719348/1860887.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/invitation-to-immunovias-q4-presentation-301750785.html